ClinicalTrials.gg
CompletedNCT06693609Updated Jul 31, 2026

Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder

A Phase 2 interventional study of EMP-01 and EMP-01 Placebo in Social Anxiety Disorder, sponsored by atai Therapeutics, Inc.. Completed at 7 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by atai Therapeutics, Inc. (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Phobia, Social with a site in United Kingdom — 1 open to participants now, 1 under way, none of them phase 3. Phobia, Social · United Kingdom.

Enrollment
6th of 10
70 · median 85
Started
2025
the only one that year
Phase 2
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
1 of 12
atai Therapeutics, Inc.

Among the 12 studies in Phobia, Social with a site in United Kingdom, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 2, and was the 12th registered.

Phobia, Social

368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.

Browse Phobia, Social studies →

Open to participants now

1 of the 12 studies in Phobia, Social with a site in United Kingdom is open now. Recruiting first, the newest first:

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Phobia, Social with a site in United Kingdom, or all of them as a file.
02

Study summary

This Phase 2 study (protocol number EMP-01-201) will determine the safety and tolerability of a short-term treatment with an oral dosage form of EMP-01 in adult participants with social anxiety disorder (SAD) and will assess exploratory efficacy of repeated doses of EMP-01 versus placebo.

Read the detailed description

This Phase 2, exploratory, multi-center, double-blind, randomized, placebo-controlled trial will enroll approximately 60 adult participants with SAD, randomized 1:1 to receive a total of 2 double-blind administrations of EMP-01 or placebo with a 4-week interval between each administration during the placebo-controlled treatment period. All participants will have their symptoms monitored for 6 weeks until the conclusion of the study. While the primary objective of the study is to assess the safety and tolerability of EMP-01 in participants with SAD, the secondary objective is to estimate any improvement in social anxiety symptoms of participants compared to placebo.

03

Conditions studied

  • Social Anxiety Disorder

Browse trials for

Keywords

  • Social Anxiety Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligibility will be assessed at Screening and will be reconfirmed on Day -1 (Baseline) based on available information, before randomization on the following day (Day 1).

Participants must meet all of the following criteria to be enrolled in this study:

Age

  1. Participants must be between 18 and 65 years of age, inclusive, at the time of signing the ICF.

    Disease Characteristics

  2. Has a current diagnosis of SAD, as defined by the , Fifth Edition Text Revision (DSM-5-TR), which is not better attributable to another psychiatric condition or to a medical condition. The diagnosis will be confirmed by the Mini-International Neuropsychiatric Interview (MINI).
  3. Clinician-administered LSAS total score ≥ 70 at Screening and Day -1.
  4. Clinician Global Impressions - Severity (CGI-S) score ≥ 4 at Screening and Day-1.

    Weight

  5. (BMI) within the range 20-34 kg/m2 (inclusive) at Screening.
  6. Able (in the investigator's opinion) to comprehend and be willing to sign an ICF, to abide by the study restrictions, and to attend all study visits.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from this study:

Medical Conditions

  1. Has a current or prior diagnosis of a schizophrenia spectrum and other psychotic disorder, substance/medication-induced psychotic disorder, bipolar and related disorder, or any disorder with psychotic features (including MDD with psychotic features), as assessed by medical history and a structured clinical interview (MINI).
  2. Has a current or prior DSM-5-TR diagnosis of a neurocognitive disorder, intellectual disorder, dissociative disorder, disruptive/impulse-control/conduct disorder, autism spectrum disorder (level 2 or 3), or cluster A and B personality disorder, as assessed by medical history and a structured clinical interview (MINI). Inclusion of individuals with a diagnosis of autism spectrum disorder level 1 may be considered at the discretion of the investigator if the participant no longer meets criteria for the condition and current functioning and/or subthreshold symptoms will not interfere with treatment or compliance in the study.
  3. Has a current DMS-5-TR diagnosis of SAD performance only sub-type, PTSD, acute stress disorder, anorexia nervosa, bulimia nervosa, or any other co-morbid psychiatric condition that dominates the clinical presentation and would interfere with experimental treatment.
  4. Has a current DMS-5-TR disorder, other than SAD, which is the primary focus of treatment. Note that participants with concurrent GAD are eligible for the study, provided that GAD is not the primary diagnosis. Participants with attention deficit hyperactivity disorder (ADHD) are eligible for the study, provided that they do not require pharmacological treatment for the condition AND if ADHD is not the primary diagnosis.
  5. Has severe current depression, as measured by a total score ≥ 16 on the QIDS-SR-16.
  6. Has a history of moderate or severe alcohol or cannabis use disorder within 1 year before Screening. Has any severity (including mild) of other substance use disorder (drug) within 1 year before Screening, as confirmed by the MINI.
  7. Has had suicidal ideation with some intent to act within 6 months before Screening or a history of suicidal behavior within the past 1 year before Screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    EMP-01

    Drug: EMP-01

  • Placebo comparator
    EMP-01 Placebo

    Drug: EMP-01 Placebo

Interventions

  • DrugEMP-01

    EMP-01 capsules

  • DrugEMP-01 Placebo

    EMP-01 placebo capsules

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent adverse events, adverse events of special interest and serious adverse events.

    Assess the safety and tolerability of EMP-01 compared with placebo (PBO) in participants with SAD.

    Time frame: Day 1 to EOS [Day 43]

  2. Incidence of clinically significant abnormalities in physical examinations, vital signs, electrocardiogram parameters, and safety laboratory results.

    Assess the safety of EMP-01 compared with placebo (PBO) in participants with SAD.

    Time frame: Day 1 [post-dose] to Day 57

  3. Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    Assess the safety of EMP-01 compared with placebo (PBO) in participants with SAD.

    Time frame: Baseline to Day 57

Secondary outcomes

  1. Liebowitz Social Anxiety Scale (LSAS)

    Change from Baseline in the Liebowitz Social Anxiety Scale (LSAS) total score at Day 43 to evaluate the treatment difference in EMP-01 compared with PBO in improving social anxiety symptoms in participants with SAD 6 weeks after initiating treatment.

    Time frame: Baseline to EOS [Day 43]

07

Study locations

7 sites
  • MAC Clinical Research - South Staffordshire
    Bridgetown, Cannock, Staffordshire S75 3DL, United Kingdom
  • MAC Clinical Research - Greater Manchester
    Manchester, Greater Manchester M13 9NQ, United Kingdom
  • MAC Clinical Research - Lancashire
    Blackpool, Lancashire FY2 0JH, United Kingdom
  • MAC Clinical Research - Merseyside
    Liverpool, Merseyside L34 1BH, United Kingdom
  • MAC Clinical Research - South Yorkshire
    Tankersley, South Yorkshire S75 3DL, United Kingdom
  • MAC Clinical Research - Teesside
    Thornaby, Stockton-on-Tees TS17 6EW, United Kingdom
  • MAC Clinical Research Centre, West Yorkshire
    Leeds, LS10 1DU, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Dec 2025, 7 months.

Of 15 phase 2 interventional studies under Phobia, Social, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 18, 2024
StartActual
May 8, 2025
Primary completionActual
Dec 10, 2025
CompletionActual
Dec 10, 2025
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06693609
Collaborators
EmpathBio, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
May 8, 2025
Primary completion
Dec 10, 2025
Completion
Dec 10, 2025
Last update
Jul 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion